Page 172 - 2020_02-Haematologica-web

C. Talati et al.
Compassionate Program. Cancer. 2012;
118(4):1014-1022.
23. Al-Ali HK, Jaekel N, Junghanss C, et al.
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma. 2012;53(1):110- 117.
24. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induc- tion chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7(9):1268-1274.
25. Arellano M, Winton E, Pan L, et al. High- dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer. 2012;118(2):428-433.
26. Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417-4423.
27. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
28. Quintas-Cardama A, Ravandi F, Liu- Dumlao T, et al. Epigenetic therapy is asso- ciated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid
leukemia. Blood. 2012;120(24):4840-4845. 29. Rizzieri DA, O'Brien JA, Broadwater G, et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer. 2009;
115(13):2922-2929.
30. Bello C, Yu D, Komrokji RS, et al.
Outcomes after induction chemotherapy in patients with acute myeloid leukemia aris- ing from myelodysplastic syndrome. Cancer. 2011;117(7):1463-1469.
31. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-2692.
32. Moorman AV, Roman E, Willett EV, et al. Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet Cytogenet. 2001;126(2):155-161.
33. Andersson A, Johansson B, Lassen C, et al. Clinical impact of internal tandem duplica- tions and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol. 2004;72(5):307- 313.
34. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elder- ly patients with acute myeloid leukemia. Blood. 2001;97(11):3589-3595.
35. Schoch C, Kern W, Krawitz P, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype.
Blood. 2001;98(12):3500.
36. Lindsley RC, Mar BG, Mazzola E, et al.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367-1376.
37. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582- 1587.
38. Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007; 109(7):1376-1383.
39. Sherman AE, Motyckova G, Fega KR, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and out- comes. Leuk Res. 2013;37(9):998-1003.
40. Oliva EN, Nobile F, Alimena G, et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;96(5):696-702.
41. Oliva EN, D'Angelo A, Martino B, et al. More concern about transfusion require- ment when evaluating quality of life in ane- mic patients. J Clin Oncol. 2002; 20(14):3182-3183.
42. Oliva EN, Finelli C, Santini V, et al. Quality of life and physicians' perception in myelodysplastic syndromes. Am J Blood Res. 2012;2(2):136-147.
406
haematologica | 2020; 105(2)